Genmab A (GMAB) Receivables - Net (2018 - 2026)

Genmab A (GMAB) has reported Receivables - Net for 6 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 23.85% year-over-year to $1.2 billion; the trailing twelve-month figure through Jun 2026 stood at $1.2 billion (up 23.85% YoY), and the FY2025 full-year result was $1.1 billion, up 21.94% from the prior year.
• Receivables - Net climbed to $1.2 billion in Q2 2026 per GMAB's latest filing, from $968.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $1.2 billion in Q2 2026 and bottomed at $536.6 million in Q4 2023.
• Historically, Receivables - Net has averaged $914.3 million across 4 years, with a median of $983.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net increased 14.26% in 2024, then soared 84.95% in 2025.
• Over 4 years, Receivables - Net stood at $536.6 million in 2023, then grew by 14.26% to $613.1 million in 2024, then jumped by 84.95% to $1.1 billion in 2025, then advanced by 8.99% to $1.2 billion in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $1.2 billion, $968.0 million, and $1.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.